All News
Epigenetics and Autoimmune Skin Disease
d
EurekAlert!
The central dogma proposed that genetic information predominantly transfers from DNA to RNA during gene expression to make a functional product protein. This absolute theory has been debunked because of the influence of the environment on how genes are transcribed.
Read Article
Activity & Pain Tolerance (3.29.2024)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com, including where you should sit in clinic and why you should worry about secondary Sjogren's in RA.
Read Article
Quote: ""I got the message. All of us get the message, sooner or later. If you get it before it's too late or before you're too old, you'll pull through all right." ~ Nat King Cole https://t.co/dtGqztmJie
Dr. John Cush RheumNow ( View Tweet)
Should all patients with #polymyalgia rheumatics be screened for #giantcellarteriitis with vascular #ultrasound? A recent viewpoint summarizes the evidence:
đź“Šprevalence of subclinical GCA may be as high as 25%
https://t.co/UL6gWRdE5R https://t.co/EAlRyNNWYt
Links:
Annals of the Rheumatic Diseases ARD_BMJ ( View Tweet)
Cohort of 158 active #RA pts (DAS28 3.6-5.6 & pain 4-7/10) found that Pain was explained by:
- 27% - Inflammation (+PDUS), no FM
- 27% - w/ FM
- 19% - w/ both FM and inflamm
- 27% (No FM, no PD) - peripheral nociceptive pain https://t.co/uM6Gw8D8D8 https://t.co/Lk0ylcBDvM
Links:
Dr. John Cush RheumNow ( View Tweet)
Systemic Score Predicts Still's Disease Severe Complications
A multinational study of adults with Still's disease found that calculating their systemic score at baseline significantly predicted the patients risk for life-threatening outcomes.
https://t.co/YB7EcWFruE https://t.co/Vcql5tZHOk
Dr. John Cush RheumNow ( View Tweet)
Research on SGLT2 inhibitors in #gout is needed. They have been shown to reduce uric acid & gout flares, and may be uricosuric or be antiinflammatory. Also decreased incident gout (by half) among at-risk patients with type 2 diabetes (HR 0.54) https://t.co/CGG9aFsgoD https://t.co/5O2f3MFL8C
Dr. John Cush RheumNow ( View Tweet)
Korean claims study of #RA & pregnancy (& adverse preg outcomes (APO), shows MTX or LEF use w/in 3 mos of conception assoc w/ incr. in APOs (aOR 2.14-.68). In 5728 preg: 1152 APOs, HCQ most commonly used, DMARD use decreased during preg. https://t.co/7UBsNdpRgx https://t.co/cY1N73FG8Q
Dr. John Cush RheumNow ( View Tweet)
Korean biologics registry study 526 Ank Spondylitis pts on TNFi > 1yr and tapered; 24.1% experienced flares. Predictors of flare included B27+, inflammatory LBP, psoriasis, SpA Fam Hx, DM, ≥50% TNFi tapering, Dz activity (ASDAS-CRP, BASFI) at tapering https://t.co/jjyMX3borT https://t.co/u0lbtfCyz1
Dr. John Cush RheumNow ( View Tweet)
GEM: Dysphagia in myositis pts is from skeletal muscle involvement, causing upper pharyngeal dysphagia, but may also manifest as dysphonia, nasal regurgitation, or aspiration (w/ risk of pneumonia). https://t.co/MOyfdCJywC
Dr. John Cush RheumNow ( View Tweet)
Cabaletta Bio announced FDA has granted Orphan Drug Designation to CABA-201, a 4-1BB-containing human CD19-CAR T cell agent, to treat systemic sclerosis. RESET (REstoring SElf-Tolerance) trial program includes the Phase 1/2 RESET-SSc trial https://t.co/Vo5jIHBrPj https://t.co/TXvFypbZdw
Dr. John Cush RheumNow ( View Tweet)
Secondary Sjogren’s Ups Rheumatoid Arthritis Severity
A Swiss observational study has shown that RA patients with concomitant Sjögren’s disease (SjD) are more likely to have a severe RA phenotype, and be less responsive to treatment.
https://t.co/4dcackIe4S https://t.co/5VZ9I7r29F
Dr. John Cush RheumNow ( View Tweet)
Autoimmune dz pts have higher risk of macular degeneration. Cleveland Clinic study of 200K AMD vs controls, finds:
- SLE (RR 1.73)
- Scleroderma (1.65)
- Psoriasis (1.48)
- Vasculitis (1.48)
- RA (1.4)
- UC &CD (~1.42)
- Sarcoid (1.42) https://t.co/RrXaaqz3Aw https://t.co/9dGoGRCBYu
Dr. John Cush RheumNow ( View Tweet)
2023 EULAR Psoriatic Arthritis Recommendations
EULAR has updated its treatment recommendations— The updated guidance includes 7 overarching principles and 11 recommendations regarding treatment strategy and pharmacological therapies.
https://t.co/ja4g5I9emg https://t.co/9pxeup5ACg
Dr. John Cush RheumNow ( View Tweet)
Our first TNR takes place 4/2 at 6:30pm ET and will focus on Success in Rheumatoid Arthritis. You won’t want to miss it!
https://t.co/86wJ323nwT https://t.co/WX1wBJ3yoo
Links:
Dr. John Cush RheumNow ( View Tweet)
Join our experts, Drs Liebowitz and Mehta, as they provide insights on the differential diagnosis and management concepts in autoinflammatory diseases. Sponsored by Novartis Pharmaceutical Corporation.
https://t.co/b9PNCOiL7q https://t.co/7n5DwdmaIQ
Dr. John Cush RheumNow ( View Tweet)
Higher Rates of Childlessness in Rheumatic Diseases
A Finnish population study shows that several rheumatic diseases may impair reproduction and pregnancy outcomes, with significantly higher rates of childlessness or fewer children overall for women.
https://t.co/pBoSBGGMxA https://t.co/j8RGT9qrKL
Dr. John Cush RheumNow ( View Tweet)
ACR Supports FY 2024 Budget
The ACR expressed strong support for several key measures included in the Fiscal Year (FY) 2024 budget.
https://t.co/rviB0yKxOd https://t.co/LY8AzsgWjX
Dr. John Cush RheumNow ( View Tweet)
September 2023, CDC’s recommended the updated 2023–2024 booster COVID Vaccine (monovalent XBB.1.5). MMWR study shows only 18% of high risk (immunocompromised) recv'd it. Vax was 38% effective at preventing COVID hospitalization https://t.co/vf5jkMkPwj https://t.co/c55SuIuaDb
Dr. John Cush RheumNow ( View Tweet)
GEM: Dysphagia in myositis pts is from skeletal muscle involvement, causing upper pharyngeal dysphagia, but may also manifest as dysphonia, nasal regurgitation, or aspiration (w/ risk of pneumonia). https://t.co/7UMHcX7suO
Dr. John Cush RheumNow ( View Tweet)